Annovis Bio, Inc. - ANVS STOCK NEWS

Annovis Bio announced positive results from its Phase II/III Alzheimer's study of Buntanetap, showing effective and safe outcomes in high-risk Alzheimer's patients, including APOE4 carriers.

The study revealed a significant dose-response in early AD patients with improvements in ADAS-Cog11 scores, showing a -3.3 points improvement over baseline and -2.3 points over placebo.

APOE4 carriers treated with 15mg Buntanetap showed a -3.15 improvement in ADAS-Cog11 scores. The drug was also deemed safe, with no reported instances of ARIA.

The trial included 318 participants, with equal numbers of APOE4 carriers and non-carriers.

Annovis is planning an 18-month Phase III trial focusing on biomarker-positive early AD patients, further validating the drug's efficacy and safety.

An investor call discussing these findings is scheduled for June 11, 2024, at 4:30 PM ET.

Annovis Bio (NYSE: ANVS) has scheduled an investor webcast for June 11, 2024, at 4:30pm ET.

The company will discuss recent developments and strategic plans for its lead drug candidate, Buntanetap, designed to treat neurodegenerative disorders like Alzheimer's and Parkinson's Diseases.

The webcast will cover recent advancements, upcoming clinical trials, and the company's future direction.

Investors and interested parties can register online for the webcast.

Annovis has published a new article in Biomolecules focusing on Posiphen's pharmacokinetics across different species. The study provides a comprehensive comparison of Posiphen's absorption and metabolism in mice, rats, dogs, and humans. Key findings include fast peak concentration in the plasma, high brain and CSF absorption, rapid clearance from the system, and prolonged retention in the brain. Posiphen's pharmacokinetics are similar in healthy individuals and patients with Alzheimer's and Parkinson's. This research offers insights into Posiphen's mechanisms, which could be critical for future clinical applications.

Annovis Bio, a clinical-stage drug platform company, provided corporate updates and announced first quarter 2024 financial results. They reported significant Phase II/III data for early Alzheimer's disease, with improved cognition and reduced Tau protein levels. Annovis plans to conduct a pivotal Phase III trial. For Parkinson's disease, Phase III data will be released in June 2024. The company also filed a patent application for neuropsychiatric indications. Financially, cash and cash equivalents decreased, but active management and funding are secured until Q4 2024. Operating expenses decreased, with a non-cash gain from a change in fair value of liability-classified warrants.

Annovis Bio, Inc. (NYSE: ANVS) announced the successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease. The unblinding process revealed an unexpected issue with blank plasma samples, causing a delay in the data announcement. Despite the setback, the company has resolved the issue and is preparing to report topline efficacy data in June.

Annovis Bio, Inc. CEO Maria Maccecchini issued a letter to stockholders discussing Phase II/III data from the Alzheimer's study. The company remains committed to developing a drug for Alzheimer's and Parkinson's diseases, despite recent setbacks. The Phase II/III study provided valuable insights for an improved Phase III trial, focusing on early and mild Alzheimer's patients.

Annovis Bio announced statistically significant Phase II/III data in patients with early Alzheimer’s disease for buntanetap, an oral molecule that reduces production of toxic proteins. The study showed a significant improvement in ADAS-Cog 11 scores in mild AD patients, with a 3.3-point improvement over placebo. Plasma Tau protein levels were reduced, supporting the efficacy. Annovis plans to conduct a Phase III trial in biomarker-positive early AD patients.

Annovis Bio, Inc. provided updates on its clinical trials for neurodegenerative diseases, including the completion of Phase III study in Parkinson's Disease and exceeding enrollment projections for Phase II/III Alzheimer's Disease trial. The company also reported positive biomarker results in plasma of Parkinson's patients. Financially, Annovis had $5.8 million in cash as of December 31, 2023, with a net loss of $22.2 million for the fourth quarter and $56.2 million for the full year of 2023.

Annovis Bio, Inc. announces new data from a Phase 1b study confirming the efficacy of buntanetap in inhibiting amyloid precursor protein translation in early Alzheimer's Disease patients. The study utilized Stable Isotope Labeling Kinetics to measure APP translation and Aβ40 levels in cerebrospinal fluid. Buntanetap demonstrated dose-dependent lowering of APP production, with no significant adverse effects reported, indicating its safety and tolerability.